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Abstract
Achieving the 2020 goals for Neglected Tropical Diseases (NTDs) requires scale-up of Mass Drug Administration
(MDA) which will require long-term commitment of national and global financing partners, strengthening national
capacity and, at the community level, systems to monitor and evaluate activities and impact.
For some settings and diseases, MDA is not appropriate and alternative interventions are required. Operational
research is necessary to identify how existing MDA networks can deliver this more complex range of interventions
equitably.
The final stages of the different global programmes to eliminate NTDs require eliminating foci of transmission
which are likely to persist in complex and remote rural settings. Operational research is required to identify how
current tools and practices might be adapted to locate and eliminate these hard-to-reach foci.
Chronic disabilities caused by NTDs will persist after transmission of pathogens ceases. Development and delivery
of sustainable services to reduce the NTD-related disability is an urgent public health priority.
LSTM and its partners are world leaders in developing and delivering interventions to control vector-borne NTDs and
malaria, particularly in hard-to-reach settings in Africa. Our experience, partnerships and research capacity allows us
to serve as a hub for developing, supporting, monitoring and evaluating global programmes to eliminate NTDs.
Contribution of LSTM to the control of Neglected
Tropical Diseases
Since its foundation, LSTM has played an important role
in global efforts against neglected tropical diseases
(NTDs). Commencing with Joseph Everret Dutton’s pio-
neering work on trypanosomiasis in 1901, the School
now host’s the Centre for Neglected Tropical Diseases
(CNTD), a key partner in global efforts against lymphatic
filariasis (LF), and the A·WOL Consortium, developing
novel treatment regimes for prevention of transmission
and alleviation of morbidity for onchocerciasis and LF.
Other major programmes of research at LSTM currently
include human African trypanosomiasis (HAT), visceral
leishmaniasis, schistosomiasis, snakebite and dengue. All
our work is conducted in partnership with researchers
from Africa, the Americas, Asia and Europe.
The School’s work extends from basic research into
the biology of parasites, vectors, their hosts and snake
venoms through applied research to develop new drugs,
diagnostics and methods of control through to assisting
national control programmes. At each of these levels,
there are synergies between NTDs as well as other dis-
eases: methods and systems used to study or control
one disease can impact on others. Crucially, ensuring
that investment in health system strengthening needed
for NTDs will be highly relevant to other conditions in1Liverpool School of Tropical Medicine, Liverpool, UK
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need of health system strengthening to improve health.
These synergies extend beyond NTDs, especially to
malaria, another important area of health research and
delivery at LSTM.
Recognising and exploiting these synergies relies on
collaboration between national programmes, commu-
nities, international organisations, clinicians, scientists,
private companies and policy makers. LSTM’s history,
partnerships and programmes means that it is uniquely
well placed to serve as a nexus to support a truly inte-
grated global programme to eliminate NTDs.
Where are we?
Many of the global programmes working against NTDs
currently rely largely on mass drug administration
(MDA) of preventive chemotherapies (e.g., schistosomia-
sis, onchocerciasis, lymphatic filariasis, soil-transmitted
helminths) and active detection and treatment of cases
(leishmaniasis, Gambian sleeping sickness). With the
notable exception of antivenom to treat snakebite, drugs
are currently donated by the pharmaceutical industry,
and in the case of MDA programmes distributed to
local communities via national public health supply
chains and volunteer community drug distributors.
The scale of the MDA programmes is exemplified by the
Global Programme to Eliminate Lymphatic Filariasis
(GPELF) which delivered a combination of albendazole
with either ivermection or diethylcarbamazine citrate to
539 million people in 53 countries in 2011 [1]. Despite
these enormous achievements of this global programme
against LF progress is fragmented [2,3]. On the one hand,
nine countries no longer require MDA and 12 have
moved to post-MDA surveillance. On the other hand, 17
of the 34 endemic countries in Africa have yet to start [4].
Achieving the 2020 goals
Priorities for MDA-diseases
To meet the 2020 goals, operational and implementation
research is needed to optimise the scale up of cost-effec-
tive and sustainable strategies, especially in fragile and
post-conflict countries where health systems are often
weak and overburdened (see CAHRD paper HS HR
FCAS). Priorities include (i) securing long-term commit-
ment of national and global financing partners, (ii)
improving the supply chain of medicines, (iii) strength-
ening national capacity to implement MDA at the com-
munity level and (iv) establishing national systems to
monitor and evaluate the activities and impact of
national programmes [4].
Priorities for Non-MDA diseases
MDA will not be adequate for a variety of diseases and
settings [5-7]. New tools and strategies are being devel-
oped to address these limitations (see CAHRD paper
NTD Tools). These include use of (i) Doxycycline in
place of ivermectin in areas where onchocerciasis and
loiasis are coendemic [7], (ii) delivery and development
of affordable and safe antivenoms with region-wide effi-
cacy [8], (iii) interventions to address the social determi-
nants of health including improved sanitation to enhance
efforts against schistosomiasis and soil-transmitted
helminths, (iv) rapid diagnostic tests (RDTs) and orally-
delivered drugs (for stage 2 treatment) to improve the
ability of health centres to diagnose and treat human
African trypanosomiasis and (v) environmental interven-
tions and vector control to benefit groups that drug-
based strategies cannot reach.
Role of vector control
Adding vector control to the current drug-based methods
will not only complement current approaches but acceler-
ate overall progress against NTDs [9]. First, attacking the
vector and parasite simultaneously reduces the overall
reproductive number. Second, several methods of vector
control act against multiple vectors: bednets and indoor
residual spraying impact on indoor-biting mosquitoes, tria-
tomine bugs and sandfly, the vectors of malaria, LF and
Chagas disease; treatment of livestock with insecticides
impacts on tsetse flies, the vectors of sleeping sickness, as
well as livestock-biting species of mosquito and sandfly.
Strengthening health systems
Third, improvements in the capacity of a health centre to
diagnose and treat one disease may improve its overall
ability to detect and treat other diseases. Against these
benefits, provision of services for the treatment and con-
trol of NTDs requires dedication of resources and deliver-
ing a more complex range of interventions may be
challenging for often overburdened health systems to deli-
ver. Adding vector control to the services delivered by,
say, a district-level health authority may be particularly dif-
ficult, especially where novel methods are being promoted,
e.g. use of baits to attract and kill vectors rather than bed-
nets or house spraying. How can health systems be
strengthened to deliver complex interventions?
Recent research undertaken by the CNTD suggests a
way forward [10]. Njelesani et al. (2014) developed a set of
monitoring and evaluation tools to determine the capacity
of laboratory systems by analysing, institutions, national
governments and international agencies [10] (see CAHRD
paper HS Capacity). This approach highlights the
strengths and limitations of not only a particular labora-
tory system but how its function is influenced by the
wider enabling environment. This analytical approach can
be broadened to evaluate and strengthen national systems
(laboratories, vector control departments, mapping depart-
ments) that are essential components of an integrated
NTD control programme.
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The shift from MDA to a more integrated approach,
combining interventions against the parasite and vector,
means that programmes to eliminate NTDs and malaria
are likely to be similar. Indeed, vector control methods
used against mosquito-borne diseases such as malaria,
LF and dengue (i.e., insecticide-treated bednets, indoor-
residual spraying, larval source management) may be
identical. Closer collaborations between institutions
working to control NTDs and malaria will facilitate
sharing of experiences and resources and allow us to
realise emerging synergies between interventions direc-
ted against NTDs and malaria, especially for disease
such as LF in Africa which is largely transmitted by the
same vector species [11-13].
Beyond 2020
Leading up to 2020, the different global programmes
working against NTDs will need to comprise a wider
range of interventions applied over a greater area, parti-
cularly in sub-Saharan Africa. Assuming that efforts to
increase funding, capacity and implementation are suc-
cessful, then the global burden disease of NTDs will
decline and with this the scale of MDA. However, two
areas will assume increasing importance: management
of disability and eliminating the last bastions of NTD.
Management of disability
Millions of people live with chronic debilitating, dis-
abling, and disfiguring conditions as a consequence of
NTD infection [14,15]. Once they become infected or
envenomed, there is often little that can be done to
reverse this debility. Global commitments have high-
lighted the importance of alleviating suffering and pro-
viding support for those infected with NTDs [1].
However, there has been significantly less progress
made establishing clinical and social programmes to
provide this support. For example in 2008, despite an
estimated 40 million individuals living with LF, only 29
of the 82 endemic countries covered by GPELF at the
time reported that they had commenced morbidity man-
agement programmes [16].
Even if NTD elimination targets are achieved, millions
of women, men and their carers will continue to require
clinical and social support including snakebite victims
suffering the chronic, typically irreversible, physically and
psychologically disabling effects of envenoming. Develop-
ing and implementing effective and sustainable models of
services to reduce the impacts of the physical and mental
disabilities caused by NTDs is an urgent public health
priority. There will also be important lessons and syner-
gies from non-communicable diseases such as asthma
(see CAHRD paper LH Cough). Considering ways to
integrate services including morbidity management pro-
grammes into existing community-based approaches will
be important when delivering any new services (from
drugs, vector control, diagnostics or social support)
within affected community. CNTD has recently piloted
new innovative community-based tool using mobile
phone technology for collecting and mapping cases of
LF. Preliminary results are excellent and the work will be
expanded across their 12 focus countries and include
additional aspects of health information and service
delivery.
Eliminating hard-to-reach foci
Progress towards the elimination of NTDs will be pat-
chy. For instance, progress will be slower in areas
affected by conflict or geographical features (e.g., moun-
tainous regions, extensive swamps, dense forest) that
hamper delivery of interventions [17,18]. Persistence of
disease in these regions will pose two important threats
to efforts against NTDs.
First, residual foci can act as a source of parasites that
can spill into areas from which the disease has been
eliminated; this risk is especially serious for vector-borne
diseases and zoonoses where vectors and reservoir hosts
are mobile. Second, the persistence of diseases foci can
contribute to institutional, funding and community fati-
gue, especially as elimination is expensive and/or and the
disease burden is small relative to other health priorities
– snakebite being a particularly pertinent example [19].
Hence the challenge facing NTD endemic countries in
the 2020s will shift from scaling up standard interven-
tions to delivering a complex suite of interventions,
which may include chemotherapy, environmental man-
agement, vector control in hard-to-reach places [17].
The delivery of these interventions will require parti-
cipation and engagement by communities affected by
these diseases, and continued donor and partnership
support. Spatial modelling of bednets in DRC found
significantly low intervention coverage in rural remote
areas, with minimal access to main cities and transport
networks [17]. This study highlights the important
gaps in coverage and the geographical factors driving
them. Similar studies would assist efforts against other
NTDs.
It is important that the difficulties of the ‘last mile’ are
anticipated and solutions established before persistent
foci lead to either re-emergence of disease or fatigue.
There are three elements to tackling this problem: (i)
rapid identification and monitoring of persistent or re-
emerging foci, (ii) delivery of interventions to contain
and ultimately eliminate the foci and (iii) maintaining
the support of communities, governments and global
partners. The requisite tools are already in use or will
be available by 2020 [9,13]. Here we outline research
concerned with delivering strategies to identify and
eliminate foci in hard-to-reach settings.
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Identifying foci
Current research is producing a rich source of data and
tools to map diseases, vectors, environmental and demo-
graphic factors [17,18,20]. These tools can provide the
basis of early-warning systems to identify sites where
disease may persist and hence guide monitoring activ-
ities. Such an early-warning system could be operated
by an international programme [21,22] working in part-
nership with national health systems, making best use of
new remote sensing products and practices as they
emerge, and in recognition that a focus threatens neigh-
bouring regions and countries [9]. Some risk factors will
be spatially and/or temporally stable (e.g. impact of alti-
tude on the bionomics of vectors and parasites), seaso-
nal (e.g., rainfall, temperature) or unpredictable (fragility
and conflict). Local communities could play an impor-
tant role in early warning systems; they will be the first
witnesses of resurgences. Research and development will
be required to develop robust systems to integrate these
data into an overall early warning and establish systems
to provide national health systems with appropriate
warnings, building on existing global early warning sys-
tems for health such as GOARN (Global Outbreak Alert
and Response Network) GLEWS (Global Early Warning
System).
Guided by a global early warning system, national and
local health systems and local communities will provide
the basis for monitoring disease. Research will identify
how RDTs and innovative monitoring systems (e.g.,
xenomonitoring vectors and reservoir hosts if appropri-
ate) can be routinely used at sentinel sites, and how
data from these can be rapidly disseminated to national
and global centres. Information systems between senti-
nel sites and the early warning system will allow rapid
updating of risk assessments [13].
Innovations will all need to be considered in terms of
their introduction, acceptability and adherence by those
affected communities [23]. They will also need to be
considered in terms of how they will be delivered within
health systems. Strategies for partnership and engage-
ment with affected communities will need to be devel-
oped and tailored to the contexts in which they are
delivered.
Containing and eliminating foci
A flexible and integrated approach will be required to
eliminate the last bastions of disease. For example, persis-
tent human African trypanosomiasis foci in West Africa
are associated with the difficulties of reaching people liv-
ing in extensive mangrove swamps [24]. Operational
research conducted in these particular settings will be
required to identify how communities might be reached.
It seems likely that some foci will persist or re-emerge
as a direct result of local economic or socio-political fac-
tors. Well-resourced professional response teams could
provide a means of containing outbreaks and then pro-
vide the basis of a team to re-establish local capacity.
Maintaining momentum
The endgame is likely to be protracted and maintaining
the support and engagement of international partners,
governments and communities is crucial. The African
Programme for Onchocerciasis Control (APOC) as well
as the GPELF use a community-directed strategy for the
distribution for MDA, which is vital to the success of
both programmes [25-27]. Understanding how to con-
tinue to empower and engage communities will be
essential to ensure momentum at the community-level
is maintained during the endgame. Research using both
qualitative (interviews with key informants, focus group
discussions with communities) and quantitative (Knowl-
edge Attitudes and Practice surveys) methods with com-
munity members and key informants will help inform
the best strategies to reach the elimination goals.
Conclusions
In the lead up to 2020, there is a pressing need to
strengthen funding and national capacity to deliver
Figure 1 Bed net coverage in DRC.[17]
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interventions against NTDs, which will be based on, but
not limited to, MDA.
In the post 2020 world, the different global pro-
grammes working against NTDs will be more focussed
on disability management and the identification and
elimination of the last bastions of disease.
Systematic analysis of capacity, interventions and
impact conducted in the lead up to 2020 will provide the
basis for developing strategies to complete ‘the last mile’.
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